We noticed that B cell receptor ligation or phorbol 12-myristate 13-acetate treatment induced intracellular vesicles containing major histocompatibility complex (MHC) class II and invariant chain (Ii), and increased the amount of transmembrane p12 Ii fragments coimmunoprecipitated with class II molecules. To determine the influence of protein kinase C activation on the MHC class II presentation pathway, we analyzed the subcellular distribution of Ii, the induction of SDS-stable forms of class II molecules, and their ability to present different antigens. Ii chains visualized with luminal and cytoplasmic directed antibodies appeared in early endosomal compartments accessible to transferrin in response to phorbol 12-myristate 13-acetate treatment, whereas transmembrane Ii degradation products equivalent to the p12 Ii fragments were colocalized with the B cell receptors internalized after cross-linking. Protein kinase C activation delayed in parallel the formation of SDS-stable forms of class II molecules and reduced the presentation of antigenic determinants requiring newly synthesized class II ␣-Ii complexes. These data indicate that B cell activation affects Ii processing and MHC class II peptide loading in endosomal compartments intersecting the biosynthetic pathway.
MHC1 class II molecules bind in their groove antigenic peptides generally derived from endocytosed proteins for their presentation to specific CD4 ϩ T lymphocytes (reviewed in Refs. 1-3). Shortly after their biosynthesis, the MHC class II ␣ and  chains assemble with Ii through a sequence from amino acid 81 to 104 of Ii called CLIP for class II associated Ii peptide (4 -6), and form (␣) 3 Ii 3 nonameric structures (7,8). Ii prevents the association of antigenic peptides with class II ␣ heterodimers (9 -11) through CLIP peptide (5), which occupies the peptidebinding groove in crystallized MHC class II molecules (12). The trimerization of Ii cytoplasmic domains, containing two dileucine motives each, drives the targeting of newly synthesized class II molecules to specialized endosomal compartments (13-15), which were further characterized as compartments of antigen processing and of peptide loading (16 -19). The amount of class II molecules located in these intracellular compartments can differ to a considerable extent, depending on the cell type (20 -23), and proteolytic cleavage of Ii occurs at this stage as indicated by ultrastructural observations (22). Upon removal of CLIP from class II molecules catalyzed by HLA-DM or its murine equivalent H2-M class II molecules (24 -26), peptide-loaded MHC class II complexes are exported to the cell surface by a poorly defined pathway. Recycling of class II molecules, from the plasma membrane through endosomes, has also been observed in B cells (27-29), allowing binding and presentation of different antigens to T cells (27,30). MHC class II molecules can therefore gain access to the antigen-processing compartments by at least two different routes, a direct targeting of newly synthesized ␣-Ii complexes and...